Trial Profile

A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary)
Indications Liposarcoma
Focus Therapeutic Use

Most Recent Events

09 Jul 2020 Results (n=196) assessing association of neutropenia with disease response to palbociclib in two studies (NCT01037790 & NCT01209598), published in the British Journal of Cancer.
05 Jun 2018 Results assessing the association between Neutropenia and response to Palbociclib in two phase II trials (NCT01037790 and NCT01209598) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
25 Apr 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com